{
  "abstract": "Middle East respiratory syndrome coronavirus (MERS-CoV) causes serious infection in humans with up to 40% mortality. As MERS-CoV infects humans via nasopharyngeal mucosa, local mucosal immunization may provide an effective vaccination strategy. Nasopharynx-associated lymphoid tissues (NALT, comprising adenotonsillar tissues) are immune induction sites for intranasal vaccines. We studied the capacity of a viral vectored MERS candidate vaccine (ChAdOx1 MERS) and inactivated MERS-CoV in activating cellular and antibody responses in the NALT. Mononuclear cells isolated from adenotonsillar tissues from children and adults were stimulated with ChAdOx1 MERS and heat- or radiation-inactivated MERS-CoV, followed by analysis of anti-MERS IgG antibody and cytokines (IFNγ and TNFα) in cell culture supernatants by ELISA. CD4+ and CD8+ T cell responses, including proliferation and expression of cytokines and cytotoxic molecules were evaluated by flow cytometry. ChAdOx1 MERS induced marked spike-specific anti-MERS IgG antibody responses, which were significantly stronger than those induced by inactivated MERS-CoV. ChAdOx1 MERS also activated higher CD4+ and CD8+ T cell proliferative responses, cytokine expression (IFNγ, TNFα) by CD4+ T cells and cytotoxic perforin and granzyme B expression by CD8+ T cells than by inactivated MERS-CoV. Both antibody and T cell responses were shown stronger in adults than in children. There was a positive correlation between CD4+ T cell proliferation and the antibody response. Human NALT offers an efficient immune induction site for Spike-specific anti-MERS antibody and T cell response. Viral vectored ChAdOx1 MERS induces marked antibody and T cell responses in the NALT, supporting its potential as a mucosal (e.g. intranasal) vaccine against MERS.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK",
    "Department of Medical Virology, Vector-Borne Diseases Laboratories, Public Health Authority, Jazan, Saudi Arabia",
    "ENT Departments, Alder Hey Children’s Hospital, Liverpool, UK",
    "ENT Departments, Aintree University Hospital, Liverpool, UK",
    "Jenner Vaccine Institute; Oxford Vaccine Group; Pandemic Sciences Institute; CAMS Oxford Institute, University of Oxford ; Chinese Academy of Medical Sciences & Peking Union Medical College, Oxford, UK",
    "Section of Immunology, Department of Microbes, Infection and Immunity, University of Surrey, Surrey, UK"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Khalid J. Shrwani"
    },
    {
      "affs": [
        2
      ],
      "name": "Ravi Sharma"
    },
    {
      "affs": [
        2
      ],
      "name": "Madhankumar Krishnan"
    },
    {
      "affs": [
        3
      ],
      "name": "Samuel Leong"
    },
    {
      "affs": [
        4
      ],
      "name": "Teresa Lambe"
    },
    {
      "affs": [
        4
      ],
      "name": "Sarah C. Gilbert"
    },
    {
      "affs": [
        0
      ],
      "name": "Nigel Cunliffe"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Qibo Zhang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4r6t2n0r3bxvg.bib",
  "cited_by": 0,
  "doi": "10.1080/21645515.2026.2756059",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757681/",
  "id": "4r6t2n0r3bxvg",
  "issns": [
    "2164-5515",
    "2164-554X"
  ],
  "landing_url": "https://doi.org/10.1080/21645515.2026.2756059",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Novel Vaccines"
    ],
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2725|SARS-CoV-2 and COVID-19 Research"
    ]
  ],
  "openalex": "W7225611194",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/21645515.2026.2756059?needAccess=true",
  "pmcid": "PMC13757681",
  "pmid": "43002445",
  "published": "2026-11-09",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/4r6t2n0r3bxvg.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:16Z",
      "native_id": "PMC13757681",
      "source": "pmc",
      "url": "https://doi.org/10.1080/21645515.2026.2756059"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2725|SARS-CoV-2 and COVID-19 Research",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV",
  "title_text": "Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:16Z",
  "url": "https://research.draconitic.com/paper/4r6t2n0r3bxvg",
  "venue": "Human Vaccines & Immunotherapeutics",
  "versions": []
}